Skip to main content
Journal of Central South University Medical Sciences logoLink to Journal of Central South University Medical Sciences
. 2023 Apr 28;48(4):608–613. [Article in Chinese] doi: 10.11817/j.issn.1672-7347.2023.220214

不引起管腔狭窄的血管中膜钙化

A nonobstructive condition: Medial arterial calcification

YANG Chenzi 1,2, SHU Chang 1,2,
Editor: 田 朴
PMCID: PMC10930249  PMID: 37385624

Abstract

Vascular calcification, including intimal and medial calcification, is closely associated with a significant increase in cardiovascular diseases. Although increased understandings were achieved, people still know much more about intimal calcification than medial calcification because the latter doesn’t obstruct the arterial lumen, commonly considered as a non-significant finding. We clarified the pathologic characteristic of medial calcification, its difference from intimal calcification, principally focused on its clinical relevance, such as diagnosis, nosogenesis, and hemodynamics. We underline the importance of identifying and distinguishing medial calcification, understanding its effect to local/systematic arterial compliance, and relationship to diabetic neuropathy. Recent studies emphasize do not ignore its predictive role in cardiovascular mortality. It is of great clinical significance to summarize the mechanisms of occurrence, lesion characteristics, diagnostic methods, pathogenic mechanisms, hemodynamic changes, and the distinction as well as association of intimal calcification with intimal calcification.

Keywords: vascular calcification, luminal stenosis, medial arterial calcification, intimal arterial calcification, osteoblastic differentiation, vascular smooth muscle cell, diabetic neuropathy


血管钙化是指羟磷灰石结晶沉积到血管,导致血管壁钙化的一种病理改变,是异位钙化的一种。按组织解剖分类有内膜钙化、中膜钙化、心脏瓣膜钙化和钙化防御4种形式[1]。其中,对内膜钙化的研究较为深入。近年来,另一种发生在血管中膜的钙化形式也逐渐被认识,并在不断研究。中膜钙化又称为Mönckeberg sclerosis,1903年由德国放射学家Mönckeberg提出,是指羟磷灰石结晶在动脉的中层平滑肌细胞或者细胞外基质中沉积,导致血管壁僵硬,血管顺应性下降[2]。早期认为中膜钙化是被动的沉积过程,随着研究的深入,发现它的形成是一个与骨发育相似的、主动的、可调控的生物学过程,其中心环节是血管平滑肌细胞(vascular smooth muscle cell,VSMC)向成骨样细胞分化。根据HE染色结果,中膜钙化的形成可以分为4个阶段:1)羟磷灰石结晶无序地沉积在中膜平滑肌细胞和细胞外基质,弹力纤维受损断裂;2)钙化范围达到血管壁的3/4;3)钙化范围达到血管壁全周,中膜结构破坏;4)出现成骨中心,真正开始骨化生[3]

1. 中膜钙化的流行病学特征

中膜钙化常见于糖尿病和肾功能不全的患者,最常发生部位在远端下肢动脉。大约21.2%的糖尿病患者可见下肢动脉中膜钙化,其发病率是正常健康人群的4倍[4]。在2型糖尿病患者中,中膜钙化发病率高达17.0%~41.5%[5-6];而在终末期肾病的患者中,其发病率为27%[7]。主动脉的中膜钙化病变多见于升主动脉和主动脉弓,且与高血压和衰老相关,在主动脉瓣膜病变的患者中其发生率明显增加[8]

2. 中膜钙化与内膜钙化的区别

中膜钙化和内膜钙化常同时发生,尽管都有VSMC表型转化的参与和钙盐沉积,但两者还是有区别(表1)。中膜钙化常见于糖尿病和慢性肾功能不全的患者,与衰老有密切联系;而内膜钙化与心血管疾病的危险因素密切相关。中膜钙化病变不突出管腔;但内膜钙化是散在、局限、偏心性的病变,突出管腔。中膜钙化无脂质沉积[9];而内膜钙化脂质成分含量高,以脂质坏死为中心,伴有炎症细胞,如巨噬、泡沫细胞的浸润。尽管两者都属于动脉硬化[10],但中膜钙化是“非粥样钙化”,内膜钙化是“粥样硬化”病变。两者发病机制不同,中膜钙化导致弹力纤维断裂,正常中膜结构破坏,血管弹性、顺应性下降,血管壁僵硬,从而导致收缩压升高,出现心功能不全;而内膜钙化是动脉粥样斑块增生突出管腔,斑块破裂引起管腔狭窄甚至闭塞。临床上,常发现糖尿病和慢性肾功能不全的患者下肢动脉钙化明显,病变对称而连续,呈现典型的中膜钙化表现,其踝肱指数(ankle brachial index,ABI)异常性升高。而动脉内膜粥样硬化患者由于下肢动脉狭窄闭塞,导致ABI下降甚至为0。有研究[9]表明中膜钙化的系统磷酸钙水平增加,钙磷稳态失衡;而内膜钙化的磷酸钙水平正常,平衡稳定。中膜钙化好发于肌性动脉,如下肢动脉,尤其在双侧腘动脉对称性出现,在冠状动脉和颈动脉中罕见[11]。中膜钙化也常见于升主动脉,当钙化范围达到升主动脉或主动脉弓全周或接近全周时,称之为瓷化主动脉(porcelain aorta,PA),是主动脉中膜钙化最严重的一种形式[12],独立于主动脉内膜钙化和粥样病变[8]。而内膜钙化最常见的部位是冠状动脉和外周动脉,无对称性。尸检中发现终末期肾功能不全患者的冠状动脉内膜钙化比例高[13]。而另有报道[14]显示肾病患者冠状动脉中膜出现钙化的比例较内膜高。因此,中膜钙化与冠状动脉的关系仍需更多研究证实[15]

表1.

中膜钙化和内膜钙化的区别

Table 1 Distinct characteristics between medial and intimal arterial calcification

项目 中膜钙化 内膜钙化
表现形式 Mönckeberg硬化 动脉粥样硬化
病因 糖尿病、慢性肾功能不全、衰老 心血管疾病的危险因素
病变形态及结局 病变连续、对称、同心;血管顺应性下降,血管僵硬,收缩压升高,导致心力衰竭

病变散在、局限、偏心;

粥样斑块增生破裂导致管腔狭窄

血管平滑肌细胞 向成骨细胞转变 增殖、迁移,向成骨细胞、泡沫细胞转化
主要信号通路 BMP2-Msx2 BMP2-Runx2
管腔狭窄 平行于管腔,不引起管腔狭窄 突出管腔,引起管腔狭窄
病变内脂质沉积
钙磷代谢 磷酸钙平衡不稳定 磷酸钙平衡稳定
好发部位

肌性动脉如下肢动脉、内脏动脉;

弹性动脉如升主动脉;冠状动脉

冠状动脉,肌性动脉如下肢动脉、颈动脉等
ABI 反常性升高 降低
X线表现 规则线状的“双轨征” 散在不规则的不透光病变

BMP2:骨形成蛋白2;Msx2:Msh同源异型基因2;Runx2:Runt相关转录因子2;ABI:踝肱指数。

3. 中膜钙化的诊断

临床上对怀疑血管病变的患者测量ABI,当ABI<0.9认为存在下肢缺血。但近年ABI异常性升高被认为是下肢动脉中膜钙化的表现之一[16]。研究[17]发现11%的合并下肢缺血的糖尿病患者ABI反常性升高。

目前ABI>1.1被认为是血管病变的诊断标准,ABI在1.1~1.3为中膜钙化早期,>1.3~1.5为中期,>1.5为晚期。尽管ABI在诊断中膜钙化中有一定的局限性,但它仍是快速筛查中膜钙化的重要指标,对于ABI升高患者可进一步行影像学检查确诊。X线摄片是临床上鉴别诊断中膜钙化及内膜钙化最常用的影像学检查。X线平片上中膜钙化表现为规则、线状的不透光“双轨征”[18];而内膜钙化则表现为不连续、不规则病变。双轨征提示病变累及血管的全周,与内膜的偏心性病变明显不同。B超下中膜钙化呈现典型的中膜“串珠状”改变;而内膜钙化呈现连续完整的中膜,彩色多普勒超声提示早期血流连续。超声检查经济、无创、无辐射,可显示血流信号。CT断层扫描也可鉴别内膜和中膜钙化[19]。对行血管介入操作的患者,腔内超声(intravascular ultrasound,IVUS)和光学相干断层成像(optical coherence tomography,OCT)也可明确有无中膜钙化[15]。但这些检查诊断中膜钙化的特异性不高,在临床的作用有待进一步验证。目前仍缺乏诊断的金标准。

4. 中膜钙化的临床意义

与内膜钙化不同,由于中膜钙化早期不引起管腔的狭窄,之前被认为没有临床意义。直到1996年芬兰的一项研究[4]表明,中膜钙化是预测非胰岛素依赖的2型糖尿病患者未来心血管事件发生的强有力标志物,才受到关注。在终末期肾病进行透析的患者中,中膜钙化也是所有死因别死亡率和心血管事件死亡率的独立预测因子[7];主动脉中膜钙化也是心血管疾病死亡率的独立危险因素[8]。糖尿病中膜钙化患者的下肢截肢率较无中膜钙化患者明显增高[6]。中膜钙化可合并动脉内膜粥样硬化,如股动脉中膜钙化的患者合并颈动脉粥样斑块的概率较正常股动脉人群大幅度增加(37.0% vs 4.1%),盆腔动脉、股动脉可同时见到内膜钙化和中膜钙化[7]。主动脉也常同时发生内膜钙化和中膜钙化,但中膜钙化多见于升主动脉和主动脉弓,内膜钙化多见于降主动脉。中膜钙化与内膜钙化的关系十分复杂,两者的机制有何异同需要进一步研究。中膜钙化多见于慢性肾脏疾病(chronic kidney disease,CKD)的早期,而CKD后期中膜钙化和内膜钙化都可出现[20]

5. 中膜钙化的血流动力学改变

中膜钙化好发于下肢动脉、升主动脉和主动脉弓。下肢动脉和主动脉分别隶属于远端肌性动脉和近端弹性动脉,两者的结构和功能不同,因此中膜钙化引起的血流动力学改变不同,对机体产生的影响也不同。弹性动脉中层富含弹力纤维,有明显的弹性和可扩张性;而肌性动脉管壁血管平滑肌含量丰富,在生理状态下保持一定的紧张性收缩,两者共同维持血管顺应性和中心动脉硬化程度。生理情况下,弹性动脉受到的周期性牵张力大,其内皮细胞产生及分泌的一氧化碳较外周肌性动脉多,因此VSMC的舒缩主要靠一氧化碳调节。随着血管树的走行,一氧化碳的分泌越来越少。在肌性动脉,VSMC的舒缩主要依靠内皮依赖性超级化(endothelium-derived hyperpolarization,EDH)以及交感缩血管纤维的作用[21],调节外周血管阻力及血压。

中膜钙化导致动脉管壁硬度增加,血管弹性降低,从而使血管收缩压升高、舒张压降低。主动脉中膜钙化由于收缩压升高引起心功能不全,下肢动脉中膜钙化主要表现为局部血流速度下降。根据魏尔啸定律,血流淤滞进一步导致血栓形成,引起下肢缺血。CKD患者的皮肤小动脉出现中膜钙化,钙化的动脉闭塞导致皮肤坏死,是CKD严重的并发症[22]。多项研究[7, 23]表明下肢动脉中膜钙化不仅影响局部血流,还可加速主动脉硬化,表现为中心脉搏波传导速度(central-pulse wave velocity,cPWV)增加,可预测心血管疾病的发生。cPWV是反映动脉弹性的重要指标,也是临床评价动脉弹性的金标准。下肢动脉中膜钙化加速主动脉硬化的原因可能是外周血管阻力增加,导致主动脉舒张压升高,使细胞外弹力纤维断裂而胶原含量增多,引起细胞外基质硬化[24]

6. 中膜钙化与动脉硬化的关系

中膜钙化和动脉硬化是2种病变。随着血管树的走行,从弹性动脉到肌性动脉,动脉弹性逐渐下降,硬度增加,cPWV增加。动脉硬化多见于近端弹性动脉[21],与弹力纤维、胶原纤维的数量和质量以及平滑肌细胞的舒缩功能相关,如当血管壁受到的机械压力增加,弹力纤维断裂而胶原含量增多,导致主动脉硬化。中膜钙化可同时累及弹性动脉和肌性动脉。中膜钙化是矿物盐在细胞外基质沉积,导致细胞外基质硬化,血管壁僵硬,从而促进动脉硬化;而VSMC具有感受细胞外基质硬度变化的能力[21],在基质硬化时,VSMC释放动脉钙化抑制因子减少,加速中膜钙化的形成。中膜钙化和动脉硬化互为因果、相互促进,形成一个恶性循环。

7. 中膜钙化的发生机制

正常情况下,血管平滑肌细胞受到交感神经的支配,维持收缩表型,分泌动脉钙化抑制因子。当内环境改变,如一氧化碳分泌减少,或者VSMC失去交感神经支配时,VSMC释放动脉钙化抑制因子的能力下降[25],骨保护素表达下降,VSMC向成骨/成软骨样细胞分化、合成和分泌多种骨形成蛋白,VSMC凋亡增加。VSMC凋亡后释放凋亡小体(基质囊泡),钙磷分子以基质囊泡为中心沉积,在中膜形成羟磷灰石结晶,发生中膜钙化。中膜钙化是典型的膜内成骨,而内膜钙化与软骨内成骨过程相似[26]。因此中膜钙化主要受骨形成蛋白2(bone morphogenetic protein 2,BMP2)-Msh同源异型基因2(Msh homeobox 2,Msx2)信号通路调节,而内膜钙化与Runt相关转录因子2(runt-related transcription factor 2,Runx2)、SRY盒转录因子9(SRY-box transcription factor 9,SOX9)关系密切[26]。敲除RunX2基因可以阻止VSMC向成骨细胞分化,抑制钙化发生,但VSMC仍可朝软骨细胞化生。尽管软骨细胞成熟存在障碍,但不能抑制核因子-κB受体激活因子配体(receptor activator of NF-κB ligand,RANKL)系统激活,无法阻止巨噬细胞介导的粥样病变形成[11]。这是首次将粥样病变和动脉钙化在基因水平上区分开来,说明内膜钙化是粥样病变和动脉钙化的结合,而中膜钙化没有脂质沉积和纤维帽形成,仅仅只发生钙化。

目前认为中膜钙化的发生与遗传因素、相关疾病(高血压、糖尿病、肾功能不全)、氧化应激、衰老、钙磷稳态失衡等因素相关,其中与糖尿病关系密切,糖尿病血管病变常伴随着中膜钙化。高血糖可通过系统和局部2种方式影响中膜钙化的发生。糖尿病患者晚期糖基化终末产物(advanced glycation end products,AGE)及其受体(receptor for AGE,RAGE)增多,通过激活多种下游信号转导通路,诱导VSMC向成骨细胞分化,促进中膜钙化发生[27]。Towler[28]提出AGE/RAGE轴在血管钙化中发挥着最为关键的作用,但其分子机制尚不十分清楚。

与AGE/RAGE的系统作用不同,糖尿病神经病变在局部起作用,早期主要是远端对称性、多发性神经病变(distal symmetric polyneuropathy,DSPN),晚期出现自主神经病变(diabetic autonomic neuropathy,DAN)。DSPN患者常发生中膜钙化[29],远端对称性神经病变导致远端对称性血管钙化。高达92%的腰交感神经节切除患者术后出现足动脉中膜钙化[30]。在接受双侧手术的患者中,93%的患者出现双侧中膜钙化;而接受单侧手术的患者,同侧和对侧足动脉中膜钙化概率分别是88%和18%,说明中膜钙化与DAN关系密切。

8. 中膜钙化的治疗

目前临床上尚无治疗中膜钙化的药物。最近有研究[31-32]发现聚腺苷二核酸核糖聚合酶[poly(ADP-ribose) polymerase,RARP]抑制剂能抑制信号转导和转录激活因子3(signal transducers and activators of transcription,STAT3)的活化,从而降低细胞外基质的钙化水平。二甲胺四环素作为RARP抑制剂,能降低大鼠超过50%的中膜钙化水平。因此,RARP抑制剂如米诺环素有望成为中膜钙化的治疗新靶点[21]。另一种在临床广泛应用的降糖药物二甲双胍,可以通过发挥多重作用抑制中膜钙化,如影响一氧化碳的产生和VSMC的表型转换[21]或抑制铁死亡[33]。成纤维细胞生长因子-2可以抑制内皮细胞向间充质细胞转化和VSMC的钙盐沉积[34-35],也是中膜钙化的潜在治疗靶点。治疗中膜钙化的另一种思路是发现和治疗其合并症,如对于慢性肾功能不全患者可采取降低血清钙磷水平、血液透析等措施[36]。对下肢动脉缺血的患者进行手术干预可缓解缺血症状,改善患者的生活质量,但对降低中膜钙化水平无帮助。

9. 结 语

不同于内膜钙化,中膜钙化有其独特的病变特点和临床意义,能更好地预测下肢截肢风险和心血管事件的死亡风险[6]。不能将血管钙化笼统地当成是内膜粥样硬化,要注意发现和区分病变中的中膜钙化,为探讨不同类型的动脉钙化与疾病之间的关系提供依据。尽管中膜钙化的发生机制被深入研究,如VSMC向成骨细胞的分化、DSPN的参与等,但中膜钙化与内膜粥样负荷的关系、对局部动脉以及主动脉弹性的影响、与心血管疾病死亡率之间的联系还需要进一步系统深入的研究。

基金资助

湖南省自然科学基金(2023JJ40866);长沙市自然科学基金(kq2014232)。

This work was supported by the National Natural Science Foundation of Hunan Province (2023JJ40866) and the Natural Science Foundation of Changsha (kq2014232), China.

利益冲突声明

作者声称无任何利益冲突。

作者贡献

杨晨紫 论文撰写与修改;舒畅 论文指导及修改。所有作者阅读并同意最终的文本。

原文网址

http://xbyxb.csu.edu.cn/xbwk/fileup/PDF/202304608.pdf

参考文献

  • 1. Lee SJ, Lee IK, Jeon JH. Vascular calcification-new insights into its mechanism[J/OL]. Int J Mol Sci, 2020, 21(8): E2685[2022-10-21]. 10.3390/ijms21082685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Villa-Bellosta R, Phosphate Egido J., pyrophosphate, and calcificationvascular : a question of balance[J]. Eur Heart J, 2017, 38(23): 1801-1804. 10.1093/eurheartj/ehv605. [DOI] [PubMed] [Google Scholar]
  • 3. Lanzer P, Boehm M, Sorribas V, et al. Medial vascular calcification revisited: review and perspectives[J]. Eur Heart J, 2014, 35(23): 1515-1525. 10.1093/eurheartj/ehu163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Moon JS, Clark VM, Beabout JW, et al. A controlled study of medial arterial calcification of legs: implications for diabetic polyneuropathy[J]. Arch Neurol, 2011, 68(10): 1290-1294. 10.1001/archneurol.2011.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Niskanen L, Siitonen O, Suhonen M, et al. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM[J]. Diabetes Care, 1994, 17(11): 1252-1256. 10.2337/diacare.17.11.1252. [DOI] [PubMed] [Google Scholar]
  • 6. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus[J]. Arterioscler Thromb Vasc Biol, 1996, 16(8): 978-983. 10.1161/01.atv.16.8.978. [DOI] [PubMed] [Google Scholar]
  • 7. London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality[J]. Nephrol Dial Transplant, 2003, 18(9): 1731-1740. 10.1093/ndt/gfg414. [DOI] [PubMed] [Google Scholar]
  • 8. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Porcelain aorta: a comprehensive review[J]. Circulation, 2015, 131(9): 827-836. 10.1161/circulationaha.114.011867. [DOI] [PubMed] [Google Scholar]
  • 9. Durham AL, Speer MY, Scatena M, et al. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness[J]. Cardiovasc Res, 2018, 114(4): 590-600. 10.1093/cvr/cvy010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Dos Santos VP, Pozzan G, Castelli V, et al. Arteriosclerosis, atherosclerosis, arteriolosclerosis, and monckeberg medial calcific sclerosis: what is the difference?[J/OL]. J Vasc Bras, 2021, 20: e20200211[2022-10-25]. 10.1590/1677-5449.200211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Lin ME, Chen TM, Wallingford MC, et al. Runx2 deletion in smooth muscle cells inhibits vascular osteochondrogenesis and calcification but not atherosclerotic lesion formation[J]. Cardiovasc Res, 2016, 112(2): 606-616. 10.1093/cvr/cvw205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Porcelain aorta: a comprehensive review[J]. Circulation, 2015, 131(9): 827-836. 10.1161/CIRCULATIONAHA.114.011867. [DOI] [PubMed] [Google Scholar]
  • 13. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure[J]. Nephrol Dial Transplant, 2000, 15(2): 218-223. 10.1093/ndt/15.2.218. [DOI] [PubMed] [Google Scholar]
  • 14. Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients[J]. Clin J Am Soc Nephrol, 2007, 2(1): 121-134. 10.2215/CJN.01760506. [DOI] [PubMed] [Google Scholar]
  • 15. Lanzer P, Hannan FM, Lanzer JD, et al. Medial arterial calcification: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2021, 78(11): 1145-1165. 10.1016/j.jacc.2021.06.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hoek AG, Zwakenberg SR, Elders PJM, et al. An elevated ankle-brachial index is not a valid proxy for peripheral medial arterial calcification[J]. Atherosclerosis, 2021, 323: 13-19. 10.1016/j.atherosclerosis.2021.03.010. [DOI] [PubMed] [Google Scholar]
  • 17. Santos VP, Alves C, Fidelis R, et al. Comparative study of the Ankle-Brachial Index in diabetic and non-diabetic patients with critical limb ischemia. J Vasc Bras. 2015;14(4): 305-10. 10.1590/1677-5449.03115. [DOI] [Google Scholar]
  • 18. Skolnik J, Weiss R, Meyr AJ, et al. Evaluating the impact of medial arterial calcification on outcomes of infrageniculate endovascular interventions for treatment of diabetic foot ulcers[J]. Vasc Endovascular Surg, 2021, 55(4): 382-388. 10.1177/1538574421993314. [DOI] [PubMed] [Google Scholar]
  • 19. Kockelkoren R, Vos A, van Hecke W, et al. Computed tomographic distinction of intimal and medial calcification in the intracranial internal carotid artery[J/OL]. PLoS One, 2017, 12(1): e0168360[2022-10-25]. 10.1371/journal.pone.0168360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease[J]. Clin J Am Soc Nephrol, 2008, 3(6): 1599-1605. 10.2215/CJN.02120508. [DOI] [PubMed] [Google Scholar]
  • 21. Van den Bergh G, Opdebeeck B, D’Haese PC, et al. The vicious cycle of arterial stiffness and arterial media calcification[J]. Trends Mol Med, 2019, 25(12): 1133-1146. 10.1016/j.molmed.2019.08.006. [DOI] [PubMed] [Google Scholar]
  • 22. Naranjo A, Rayess N, Ryan E, et al. Retinal artery and vein occlusion in calciphylaxis[J]. Am J Ophthalmol Case Rep, 2022, 26: 101433. 10.1016/j.ajoc.2022.101433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Husmann M, Jacomella V, Thalhammer C, et al. Markers of arterial stiffness in peripheral arterial disease[J]. Vasa, 2015, 44(5): 341-348. 10.1024/0301-1526/a000452. [DOI] [PubMed] [Google Scholar]
  • 24. Dao HH, Essalihi R, Bouvet C, et al. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension[J]. Cardiovasc Res, 2005, 66(2): 307-317. 10.1016/j.cardiores.2005.01.012. [DOI] [PubMed] [Google Scholar]
  • 25. Ho CY, Shanahan CM. Medial arterial calcification: an overlooked player in peripheral arterial disease[J]. Arterioscler Thromb Vasc Biol, 2016, 36(8): 1475-1482. 10.1161/ATVBAHA.116.306717. [DOI] [PubMed] [Google Scholar]
  • 26. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective[J]. Am J Physiol Endocrinol Metab, 2004, 286(5): E686-E696. 10.1152/ajpendo.00552.2003. [DOI] [PubMed] [Google Scholar]
  • 27. Kennon AM, Stewart JA. RAGE differentially altered in vitro responses in vascular smooth muscle cells and adventitial fibroblasts in diabetes-induced vascular calcification[J]. Front Physiol, 2021, 12: 676727. 10.3389/fphys.2021.676727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Towler DA. Vascular calcification: it’s all the RAGE![J]. Arterioscler Thromb Vasc Biol, 2011, 31(2): 237-239. 10.1161/ATVBAHA.110.220038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Edmonds ME, Roberts VC, Watkins PJ. Blood flow in the diabetic neuropathic foot[J]. Diabetologia, 1982, 22(1): 9-15. 10.1007/bf00253862. [DOI] [PubMed] [Google Scholar]
  • 30. Goebel FD, Füessl HS. Mönckeberg’s sclerosis after sympathetic denervation in diabetic and non-diabetic subjects[J]. Diabetologia, 1983, 24(5): 347-350. 10.1007/BF00251822. [DOI] [PubMed] [Google Scholar]
  • 31. Müller KH, Hayward R, Rajan R, et al. Poly(ADP-ribose) links the DNA damage response and biomineralization[J]. Cell Rep, 2019, 27(11): 3124-3138.e13. 10.1016/j.celrep.2019.05.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Wang C, Xu WJ, An J, et al. Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2[J]. Nat Commun, 2019, 10(1): 1203. 10.1038/s41467-019-09174-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ma WQ, Sun XJ, Zhu Y, et al. Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects[J]. Free Radic Biol Med, 2021, 165: 229-242. 10.1016/j.freeradbiomed.2021.01.033. [DOI] [PubMed] [Google Scholar]
  • 34. Correia ACP, Moonen JR AJ, Brinker MGL, et al. FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGFβ signaling[J]. J Cell Sci, 2016, 129(3): 569-579. 10.1242/jcs.176248. [DOI] [PubMed] [Google Scholar]
  • 35. Borland SJ, Morris TG, Borland SC, et al. Regulation of vascular smooth muscle cell calcification by syndecan-4/FGF-2/PKCα signalling and cross-talk with TGFβ[J]. Cardiovasc Res, 2017, 113(13): 1639-1652. 10.1093/cvr/cvx178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Thomas DC, Thomas P, Sivan A, et al. Monckeberg’s medial sclerosis as a cause for headache and facial pain[J]. Curr Pain Headache Rep, 2021, 25(8): 50. 10.1007/s11916-021-00965-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Central South University Medical Sciences are provided here courtesy of Central South University

RESOURCES